Quality of Life Introduction Disorders of the anorectal region are a frequent cause of patient visits to both primary care and specialist clinics, impacting comfort, daily activities, and quality of life
In STEP 1 (NEJM 2021), FDA-approved semaglutide 2.4 mg with lifestyle support produced a mean 14.9% body weight reduction at 68 weeks versus 2.4% with placebo
Comparing the results of phase 2 clinical trials of these two drugs (baseline characteristics of populations were similar), 51,52 tirzepatide seemed to be more efficacious in improving T2DM
Bariatric Surgery as an Alternative to Semaglutide In addition to weight loss medication options, some patients may consider bariatric surgery as a long-term solution for obesity and related conditions
Plan on at least a few weeks of inactivity, swelling, pain management, compression garments, and follow-ups